SKYE
Skye Bioscience, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.11
−9.02%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$1.21
From 52W high−90.93%
Volume34234.00
Market cap$4.91M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$1.21
From 52W high
−90.93%
Volume
34234.00
Market cap
$4.91M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.1x
P/E (TTM)
—
RSI (14)
30.4
MomentumView details →
1D Return
−9.02%
YTD Return
−79.67%
SummaryUpdated Jun 1, 2026
Skye Bioscience, Inc. (NASDAQ:SKYE) is a clinical-stage biopharmaceutical company founded in 2012 and headquartered in San Diego, California. Originally established as Emerald Bioscience, Inc., the company rebranded to Skye Bioscience in January 2021. The company went public in November 2014 and has evolved from developing cannabinoid-based treatments for eye diseases to focusing primarily on obesity therapeutics through its lead drug candidate nimacimab.
Similar companies
Latest newsMore news →
Skye Bioscience entered into a securities purchase agreement to sell up to $22 million of its common and non-voting common stock to Redmile Biopharma Investments III, L.P. over a three-year term, and issued a warrant to purchase up to $5 million of shares.73d agoSkye Bioscience, Inc. received a notice from NASDAQ on August 18, 2026, stating that the company no longer complies with the minimum stockholders' equity requirement of Rule 5550(b)(1), and must achieve at least $2,500,000 in stockholders' equity by October 2, 2026, to regain compliance.78d ago